Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. noratest

NORATEST SIGNED

NORATEST: An e-Health solution for a better Alzheimer's diagnosis and management

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NORATEST project word cloud

Explore the words cloud of the NORATEST project. It provides you a very rough idea of what is the project "NORATEST" about.

revenue    countries    2050    suffering    competitive    care    privacy    computer    reference    discriminate    accumulate    platform    2    alzohis    earn    80m    motivated    cagr    5    trl6    health    total    algorithm    54m    worth    fast    detectable    efficient    5m    usa    market    2026    ddiagnosis    analytics    efficiency    diagnoses    detecting    online    improvements    profit    roi    prototype    almost    invasive    annual    pay    gt    sales    17    2030    worldwide    tests    signatures    shows    ones    stages    accounting    anticipating    combined    business    lack    adaptable    detection    patients    ad    smart    data    diseases    360k    employees    global    biomarkers    detect    32m    12    charging    disease    innovative    molecular    direct    accurate    producing    blood    duplicating    people    affordable    leaders    model    combination    speed    markets    alzheimer    diagnosis    noratest    company    neurodegenerative    diagnostic    hire    advantages    medical    2016    first    coupled    2024    issue    dementia    projected    healthy    scalable    solution   

Project "NORATEST" data sheet

The following table provides information about the project.

Coordinator		 ALZOHIS 

Organization address
address: RUE DU FAUBOURG POISSONNIERE 28
city: PARIS
postcode: 91400
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ALZOHIS FR (PARIS) coordinator 50˙000.00

Map

 Project objective

Alzheimer's disease (AD) is a major medical problem and is currently an issue of global general interest as the total number of people with dementia is projected to reach ~80M in 2030 and almost duplicating this number by 2050. The lack of an efficient and affordable solution in the AD's health care sector has motivated our company Alzohis to develop NORATEST, a very unique and innovative e-Health platform producing significant improvements, in terms of speed efficiency, in the detection of neurodegenerative diseases. By means of a novel combination of biomarkers “signatures” detectable in the blood with a state-of-the-art computer algorithm NORATEST can discriminate patients suffering AD from those healthy ones, as well as detecting other neurodegenerative diseases. Our prototype, currently at TRL6, is the first reliable non-invasive molecular diagnostic method able to detect the disease in the very early stages, offering several competitive and innovative advantages such as: Cost-effective novel technology, fast, accurate, early ddiagnosis, data privacy coupled to smart analytics, user-friendly and highly scalable and adaptable platform. Our business model is a pay-per-use combined model of charging per analysis and direct online sales. The global AD market shows great opportunities for us since it was worth €2.5 B in 2016 and is set to reach €12.6 B by 2026 (CAGR of 17.5%). Worldwide we expect a market growth in both established and in developing countries, anticipating >5M annual AD's diagnoses in the two main markets leaders based in Europe (2.5-3.5M diagnoses/year) and USA (1.5-2.5M diagnoses/year) by 2024. Our company goal is to become the reference for AD's diagnosis in Europe. We estimated that in 5 years (end of Phase 2 project), we will accumulate 360K diagnosis tests sales (revenue €54M) accounting for ~2% of the EU and USA market. We expect to hire 40 new technical and sales employees and earn ~€32M profit, with a ROI of 6.5.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NORATEST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NORATEST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

MIGRATECH 4.0 (2019)

The revolution in micro-granulation technology for eco-friendly, production efficient, superior ceramic tiles

Read More